The EVOKE-01 study investigated Trodelvy against docetaxel in patients with advanced non-small cell lung cancer (NSCLC) that had progressed after standard treatments.
The study revealed a 16% reduction in mortality risk for patients treated with Trodelvy compared to docetaxel (median overall survival: 11.1 vs. 9.8 months). This improvement was observed across all disease types.
A significant OS benefit was observed in patients whose tumors did not respond to previous anti-PD-(L)1 therapy, with a 3.5-month improvement in median OS (11.8 vs. 8.3 months). This subgroup accounted for approximately two-thirds of the study participants.
In patients whose tumors responded to previous anti-PD-(L)1 therapy, median OS was longer with docetaxel (10.6 months) than with Trodelvy (9.6 months).
The study also demonstrated a lower incidence of severe side effects and treatment discontinuations with Trodelvy than docetaxel. The most common side effects of Trodelvy included fatigue, diarrhea, and hair loss.
These findings suggest that Trodelvy could be a valuable second-line treatment option for patients with advanced NSCLC who have progressed on prior therapies, especially those whose tumors are resistant to anti-PD-(L)1 therapy.
Further research is needed to confirm these findings and explore the optimal use of Trodelvy in treating advanced NSCLC.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
